Literature DB >> 11714895

Effects of infusion rate of intravenously administered morphine on physiological, psychomotor, and self-reported measures in humans.

L A Marsch1, W K Bickel, G J Badger, J P Rathmell, M D Swedberg, B Jonzon, C Norsten-Höög.   

Abstract

Although the rate of onset of a drug effect is commonly believed to contribute to a drug's abuse liability, only a few systematic experimental studies have been conducted examining this notion. The present study determined the profile of physiological, psychomotor, and self-reported effects of infusion rate (a key means of manipulating onset of drug action) of intravenously administered morphine, the prototypical analgesic with a known abuse liability in human participants. Two doses of morphine sulfate (5 and 10 mg/70 kg, i.v.) and a placebo dose (0 mg/70 kg, i.v.) were administered to healthy volunteers under three infusion rates (2 min bolus, 15 min, and 60 min). Faster infusions of morphine produced greater positive subjective effects than slower infusions on visual analog scale measures of good drug effect, drug liking, and high. Faster infusions also resulted in greater self-reported drug effects and opioid agonist effects, without producing significant physiological or psychomotor impairment. Importantly, faster rates of drug infusion produced significantly higher morphine plasma levels than slower rates, and morphine plasma levels followed a similar pattern and timing of peak effect as the self-reported effects of the drug. Moreover, morphine produced dose-dependent increases in self-reported drug effects, opioid agonist effects, and morphine plasma levels in the study. Results suggest that the pharmacokinetic properties of a drug, including the dosage administered and the rate of at which it is administered may function to jointly affect the abuse liability of the drug.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714895

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  44 in total

1.  Smoking produces rapid rise of [11C]nicotine in human brain.

Authors:  Marc S Berridge; Scott M Apana; Kenichi K Nagano; Catherine E Berridge; Gregory P Leisure; Mark V Boswell
Journal:  Psychopharmacology (Berl)       Date:  2010-03-16       Impact factor: 4.530

2.  Assessment of a formulation designed to be crush-resistant in prescription opioid abusers.

Authors:  Suzanne K Vosburg; Jermaine D Jones; Jeanne M Manubay; Judy B Ashworth; Irma H Benedek; Sandra D Comer
Journal:  Drug Alcohol Depend       Date:  2012-06-20       Impact factor: 4.492

3.  Faster onset and dopamine transporter selectivity predict stimulant and reinforcing effects of cocaine analogs in squirrel monkeys.

Authors:  Heather L Kimmel; Joann A O'Connor; F Ivy Carroll; Leonard L Howell
Journal:  Pharmacol Biochem Behav       Date:  2006-12-20       Impact factor: 3.533

Review 4.  Misuse of and dependence on opioids: study of chronic pain patients.

Authors:  Meldon Kahan; Anita Srivastava; Lynn Wilson; Douglas Gourlay; Deana Midmer
Journal:  Can Fam Physician       Date:  2006-09       Impact factor: 3.275

Review 5.  Abuse-deterrent opioid formulations: are they a pipe dream?

Authors:  Nathaniel Katz
Journal:  Curr Rheumatol Rep       Date:  2008-01       Impact factor: 4.592

Review 6.  Maintenance medication for opiate addiction: the foundation of recovery.

Authors:  Gavin Bart
Journal:  J Addict Dis       Date:  2012

7.  Varying the rate of intravenous cocaine infusion influences the temporal dynamics of both drug and dopamine concentrations in the striatum.

Authors:  Ellie-Anna Minogianis; Waqqas M Shams; Omar S Mabrouk; Jenny-Marie T Wong; Wayne G Brake; Robert T Kennedy; Patrick du Souich; Anne-Noël Samaha
Journal:  Eur J Neurosci       Date:  2018-07-24       Impact factor: 3.386

8.  Characterizing the relationship between increases in the cost of nicotine and decreases in nicotine content in adult male rats: implications for tobacco regulation.

Authors:  Tracy T Smith; Laura E Rupprecht; Alan F Sved; Eric C Donny
Journal:  Psychopharmacology (Berl)       Date:  2016-09-14       Impact factor: 4.530

9.  Can abuse deterrent formulations make a difference? Expectation and speculation.

Authors:  Simon H Budman; Jill M Grimes Serrano; Stephen F Butler
Journal:  Harm Reduct J       Date:  2009-05-29

10.  Challenges in using opioids to treat pain in persons with substance use disorders.

Authors:  Seddon R Savage; Kenneth L Kirsh; Steven D Passik
Journal:  Addict Sci Clin Pract       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.